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Exacerbation of COPD: transforming outcomes through research 
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“Would you tell me, please, which way I ought to go from here?" 
"That depends a good deal on where you want to get to." [1]. 
 
The time has come for a revolution in the prevention and mitigation of exacerbations in chronic 
obstructive pulmonary disease (COPD).  In the UK, recent national audit data demand urgent 
attention.  Admissions to hospital for COPD exacerbations have risen by 13% since 2008, to 115,000 
/year [2].  In-patient mortality is 4%, and a further 3% will die and 24% will be re-admitted to 
hospital within 30 days of discharge [2].  There are unexplained variations in care-quality that 
exaggerate the health inequalities already associated with COPD.  And these concerning statistics on 
secondary care admissions represent just a small proportion of the overall burden of exacerbations. 
At the most basic level we still have a problem with terminology.  It is impossible to have an 
exacerbation of COPD if a person does not have COPD, yet the lack of access to - or willingness to 
access –confirmatory quality-assured diagnostic spirometry results at the time a patient presents 
with exacerbation is of considerable concern [2].  The definition and diagnostic criteria for COPD 
exacerbation remain imperfect.  The GOLD strategy document defines exacerbation as a change in 
symptoms requiring additional therapy [3].  In everyday-practice exacerbation is a clinical diagnosis 
of exclusion, suggested by changes in symptoms, but only made when the clinician has considered 
and where appropriate excluded other causes of symptom changes in a patient with known COPD.  
Despite considerable effort, there remains no diagnostic test for exacerbation that is sufficiently 
sensitive or specific to rule-in and rule-out exacerbation from other causes of symptoms changes, or 
to differentiate exacerbation of COPD from COPD in the stable state [4]. 
Current interventions to treat COPD are inadequate.  Remarkably, there have been no new 
interventions to treat COPD exacerbations in our entire professional lifetime of over 20 years.  The 
evidence for oral steroids is weak and based on outcomes that do not focus on the patient – typically 
speed of improvement in lung function [5].  Avoidable morbidity from over-use of steroids is 
considerable and, as commonly employed in ‘rescue packs’, it is known that not all patients are able 
to self-manage appropriately [6].  Over-use of antibiotics risks development of anti-microbial 
resistance in the individual, and in our societies.  We have no reliable methods to differentiate 
bacterial, viral or environmental exacerbations at the point of care and, in any case, we have no 
effective anti-viral interventions to treat rhinovirus – the commonest single cause of COPD 
exacerbations.  Our fundamental understanding of the biology of a COPD exacerbation is 
incomplete, limiting therapeutic developments.  Although it is now accepted that exacerbations are 
not all the same and can be ‘phenotyped’ [7], initial evidence to support a stratified medicine 
approach - better targeting of steroids (using blood eosinophils [8]) and/ or antibiotics (using 
biomarkers such as CRP, procalcitonin or indeed sputum colour) have not been translated into 
routine clinical practice.  Anecdotally, patients have long-acting bronchodilators stopped in 
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preference to nebulised short-acting drugs.  Patients still experience iatrogenic oxygen toxicity [2].  
Attention to co-morbidities is poor despite the increasing prevalence of an ageing, multi-morbid 
patient population with poly-pharmacy.  We welcome the move to a rolling UK national COPD audit 
programme [2] as a tool for quality improvement – specialist review at the front door and an 
evidence-based bundle of interventions prior to discharge – but also needed is a revolution in the 
evidence base for exacerbation treatment: both better use of existing interventions and the rapid 
development and testing of new interventions (anti-inflammatories, for example) based upon a 
deeper understanding of fundamental disease mechanisms. 
Better communication and closer working across hospital clinicians, community-based teams, and 
primary care may be one way to mitigate the risks of repeat admission.  An exacerbation event 
should be used as an opportunity to review the patient’s preventative strategies.  There are data to 
support the idea that the timing of exacerbation events is not random, with a higher-risk for repeat 
exacerbation in the recovery period from a first [9].  Reducing the risk, and consequences arising 
from a first hospitalised exacerbation therefore appears particularly important and thus how best to 
reduce the risk of readmission is a major unanswered problem.  Patients susceptible to frequent 
exacerbations, a relatively stable phenotype [10], experience an excess burden of disease. 
We do, at least, have interventions that can to some degree reduce the risk of exacerbations.  
Current strategies achieve, at most, a 25% reduction suggesting that 75% of events remain 
unmitigated.  Even this assumes appropriate targeting, however it is clear that exacerbation 
reduction interventions remain poorly focused with considerable under- and over-treatment and 
therefore avoidable morbidity and excess health-care cost.  Additional challenges include translating 
the benefit from interventions seen in high-quality randomised trials to the real life multi-morbid 
patients that dominate clinical practice.  High value interventions include vaccinations and 
pulmonary rehabilitation [11], supplemented by judicious use of pharmacotherapy, which for many 
people should now be based on one or more long-acting bronchodilators [3].  Evidence to support 
robust identification of groups most likely to benefit (or not) from inhaled corticosteroids remain in 
evolution, and careful targeting of novel therapies is of increasing importance with the emergence of 
evidence to support the use of biologicals including anti-eosinophil strategies. 
At a global scale the challenges managing COPD and COPD exacerbations are even greater.  90% of 
COPD deaths occur in low- and middle-income countries (LMIC), where much COPD is associated 
with household air pollution from biomass and solid fuels, in addition to that associated with 
tobacco smoke exposure [12].  There is very little known about the biology of exacerbations in 
biomass COPD, or about the most appropriate strategies for exacerbation prevention and treatment 
in LMIC.  Clearly, in all settings, exposure reduction initiatives provide the best opportunity to reduce 
the burden of COPD in future generations. 
We argue that with an ageing and multi-morbid population, a revolution in the care and prevention 
of COPD exacerbations is urgently required – across all health-care settings.  Clinicians should not 
accept exacerbations as inevitable.  We need new, high-quality evidence to better target existing 
interventions, incompletely effective as they are, and the ability to rapidly test and implement new 
exacerbation prevention and treatment strategies - in real-world settings.  Research funding must be 
directed to better understand the fundamental biology of exacerbations if we are to develop new 
therapies.  The UK COPD national audit programme, when appropriately resourced in individual 
units, can measure the implementation of interventions and help assess impact on outcomes.  This 
unique tool for quality improvement provides learning opportunities for other health-systems.  Only 
by acting urgently, with renewed enthusiasm, can we hope to reduce the current inadequate and 
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unequal care for people living with COPD, and improve exacerbation experience and outcomes.  We 
know where we are going.  We know how to get there.  It is now time for all of us to act. 
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